vs
Esperion Therapeutics, Inc.（ESPR）与MACERICH CO（MAC）财务数据对比。点击上方公司名可切换其他公司
MACERICH CO的季度营收约是Esperion Therapeutics, Inc.的1.6倍（$261.7M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -4.4%），过去两年MACERICH CO的营收复合增速更高（12.0% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Macerich是一家专注于购物中心投资的房地产投资信托基金，为美国第三大购物中心持有及运营商。截至2024年12月31日，公司共持有43处物业的权益，可租赁总面积达4300万平方英尺，公司名称由创始人Mace Siegel与Richard Cohen的名字组合而来。
ESPR vs MAC — 直观对比
营收规模更大
MAC
是对方的1.6倍
$168.4M
营收增速更快
ESPR
高出148.1%
-4.4%
两年增速更快
MAC
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $261.7M |
| 净利润 | — | $-18.8M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | — |
| 净利率 | — | -7.2% |
| 营收同比 | 143.7% | -4.4% |
| 净利润同比 | — | 91.1% |
| 每股收益（稀释后） | $0.32 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRMAC
| Q4 25 | $168.4M | $261.7M | ||
| Q3 25 | $87.3M | $253.3M | ||
| Q2 25 | $82.4M | $249.8M | ||
| Q1 25 | $65.0M | $249.2M | ||
| Q4 24 | $69.1M | $273.7M | ||
| Q3 24 | $51.6M | $220.2M | ||
| Q2 24 | $73.8M | $215.5M | ||
| Q1 24 | $137.7M | $208.8M |
净利润ESPRMAC
| Q4 25 | — | $-18.8M | ||
| Q3 25 | $-31.3M | $-87.4M | ||
| Q2 25 | $-12.7M | $-40.9M | ||
| Q1 25 | $-40.5M | $-50.1M | ||
| Q4 24 | — | $-211.2M | ||
| Q3 24 | $-29.5M | $-108.2M | ||
| Q2 24 | $-61.9M | $252.0M | ||
| Q1 24 | $61.0M | $-126.7M |
营业利润率ESPRMAC
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — | ||
| Q1 24 | 52.5% | — |
净利率ESPRMAC
| Q4 25 | — | -7.2% | ||
| Q3 25 | -35.9% | -34.5% | ||
| Q2 25 | -15.4% | -16.4% | ||
| Q1 25 | -62.2% | -20.1% | ||
| Q4 24 | — | -77.2% | ||
| Q3 24 | -57.2% | -49.1% | ||
| Q2 24 | -83.9% | 116.9% | ||
| Q1 24 | 44.3% | -60.7% |
每股收益（稀释后）ESPRMAC
| Q4 25 | $0.32 | $-0.08 | ||
| Q3 25 | $-0.16 | $-0.34 | ||
| Q2 25 | $-0.06 | $-0.16 | ||
| Q1 25 | $-0.21 | $-0.20 | ||
| Q4 24 | $-0.14 | $-0.95 | ||
| Q3 24 | $-0.15 | $-0.50 | ||
| Q2 24 | $-0.33 | $1.16 | ||
| Q1 24 | $0.34 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $280.2M |
| 总债务越低越好 | — | $5.1B |
| 股东权益账面价值 | $-302.0M | $2.4B |
| 总资产 | $465.9M | $8.4B |
| 负债/权益比越低杠杆越低 | — | 2.07× |
8季度趋势，按日历期对齐
现金及短期投资ESPRMAC
| Q4 25 | $167.9M | $280.2M | ||
| Q3 25 | $92.4M | $290.2M | ||
| Q2 25 | $86.1M | $131.1M | ||
| Q1 25 | $114.6M | $253.2M | ||
| Q4 24 | $144.8M | $89.9M | ||
| Q3 24 | $144.7M | $116.5M | ||
| Q2 24 | $189.3M | $70.7M | ||
| Q1 24 | $226.6M | $120.1M |
总债务ESPRMAC
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $5.2B | ||
| Q1 25 | — | $5.2B | ||
| Q4 24 | — | $4.9B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $4.4B | ||
| Q1 24 | — | $4.1B |
股东权益ESPRMAC
| Q4 25 | $-302.0M | $2.4B | ||
| Q3 25 | $-451.4M | $2.5B | ||
| Q2 25 | $-433.5M | $2.6B | ||
| Q1 25 | $-426.2M | $2.7B | ||
| Q4 24 | $-388.7M | $2.8B | ||
| Q3 24 | $-370.2M | $2.5B | ||
| Q2 24 | $-344.2M | $2.5B | ||
| Q1 24 | $-294.3M | $2.3B |
总资产ESPRMAC
| Q4 25 | $465.9M | $8.4B | ||
| Q3 25 | $364.0M | $8.4B | ||
| Q2 25 | $347.1M | $8.7B | ||
| Q1 25 | $324.0M | $8.7B | ||
| Q4 24 | $343.8M | $8.6B | ||
| Q3 24 | $314.1M | $7.6B | ||
| Q2 24 | $352.3M | $7.8B | ||
| Q1 24 | $373.1M | $7.4B |
负债/权益比ESPRMAC
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 2.02× | ||
| Q2 25 | — | 2.02× | ||
| Q1 25 | — | 1.96× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.73× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.79× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $50.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRMAC
| Q4 25 | $45.2M | $50.2M | ||
| Q3 25 | $-4.3M | $112.4M | ||
| Q2 25 | $-31.4M | $70.5M | ||
| Q1 25 | $-22.6M | $88.5M | ||
| Q4 24 | $-35.0M | $54.9M | ||
| Q3 24 | $-35.3M | $100.0M | ||
| Q2 24 | $-7.2M | $67.4M | ||
| Q1 24 | $53.8M | $61.1M |
自由现金流ESPRMAC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
自由现金流率ESPRMAC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
资本支出强度ESPRMAC
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率ESPRMAC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.27× | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
MAC
暂无分部数据
